Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
P 1 (3)
P 2 (1)

Trial Status

Recruiting3
Active Not Recruiting2
Not Yet Recruiting1

Clinical Trials (6)

Showing 6 of 6 trials
NCT07038369Phase 1Active Not Recruiting

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

NCT07374809Not ApplicableNot Yet RecruitingPrimary

IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER

NCT06129604Phase 2Active Not Recruiting

Pilot Window of Opportunity Trial (POET)

NCT07070518Phase 1Recruiting

Study of GV20-0251 in Participants With Solid Tumor Malignancies

NCT06893861RecruitingPrimary

Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer

NCT05669430Phase 1Recruiting

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Showing all 6 trials

Research Network

Activity Timeline